International Research Journal of Oncology

Outlook on Genetically Engineered CAR T-Cell Therapies for Solid Tumours

Yana Pautova *

Hematology/Oncology Medical Science and Strategy, QVIA, Russia.

Yuri Tolkunov

Hematology/Oncology Medical Science and Strategy, QVIA, Russia.

Luis Mendoza

Hematology/Oncology Medical Science and Strategy, IQVIA, Czech Republic.

Brian Churchill

Medical Science and Strategy, IQVIA, India.

*Author to whom correspondence should be addressed.

---

Abstract

T-cell-based methods using genetic engineering technology are considered the most advanced treatments in cancer therapy. Chimeric antigen receptor (CAR) T-cell therapy is an innovative immunotherapy wherein autologous T-cells are genetically modified to recognize and destroy cancer cells more effectively. CAR T-cell therapy has shown remarkable success in the treatment of CD19-expressing hematologic malignancies. However, such extraordinary experience has not been translated to treatment of solid tumors, where its efficacy remains limited. This article gives an overview of these obstacles that CAR T-cells research needs to overcome to achieve efficient next-generation T-cell therapy for solid malignancies.

Keywords: CAR T-cell therapy, solid tumours, clinical trials, T-cells

---

---